![Stéphane Pion](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stéphane Pion
Director/Board Member at PainCeptor Pharma Corp.
Profile
Dr. Pion holds a Ph.D.
degree in Immunology from the Université de Montréal, having conducted his doctorate studies at the Maisonneuve-Rosemont Hospital.
He joined T2C2/Bio in 1998 and is very active in the domain of information technology.
Stéphane Pion active positions
Companies | Position | Start |
---|---|---|
PainCeptor Pharma Corp.
![]() PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Director/Board Member | - |
Former positions of Stéphane Pion
Companies | Position | End |
---|---|---|
Transfer Technologies Commercialisation Capital
![]() Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Private Equity Analyst | - |
Training of Stéphane Pion
University of Montréal | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Transfer Technologies Commercialisation Capital
![]() Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Finance |
PainCeptor Pharma Corp.
![]() PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Health Technology |
- Stock Market
- Insiders
- Stéphane Pion